Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated:  1/28/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated: 1/28/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated:  1/28/2015
Clinical Research Facility
mi
from
Murray, UT
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Status: Enrolling
Updated: 1/28/2015
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Investigation of Brain Network Dynamics in Depression
Investigation of Cortico-limbic Networks and Their Dynamics in Major Depressive Disorder
Status: Enrolling
Updated:  1/30/2015
Martinos Center for Biomedical Imaging/Massachusetts General Hospital
mi
from
Charlestown, MA
Investigation of Brain Network Dynamics in Depression
Investigation of Cortico-limbic Networks and Their Dynamics in Major Depressive Disorder
Status: Enrolling
Updated: 1/30/2015
Martinos Center for Biomedical Imaging/Massachusetts General Hospital
mi
from
Charlestown, MA
Click here to add this to my saved trials
Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients
Pilot Trial of Phototherapy for Acute Depression in Hospitalized CF Patients
Status: Enrolling
Updated:  2/2/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients
Pilot Trial of Phototherapy for Acute Depression in Hospitalized CF Patients
Status: Enrolling
Updated: 2/2/2015
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Raloxifene and Rimostil for Perimenopause-Related Depression
The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression
Status: Enrolling
Updated:  2/26/2015
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Raloxifene and Rimostil for Perimenopause-Related Depression
The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression
Status: Enrolling
Updated: 2/26/2015
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ketamine in the Treatment of Depression
The Antidepressant Action of Ketamine: Brain Chemistry
Status: Enrolling
Updated:  3/6/2015
Columbia University/New York State Psychiatric Institute
mi
from
New York, NY
Ketamine in the Treatment of Depression
The Antidepressant Action of Ketamine: Brain Chemistry
Status: Enrolling
Updated: 3/6/2015
Columbia University/New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Little Rock, AR
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Beverly Hills, CA
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Miami, FL
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
North Miami, FL
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
North Miami, FL
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Orlando, FL
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Winter Park, FL
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Marietta, GA
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Smyrna, GA
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Smyrna, GA
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Oakbrook Terrace, IL
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Oakbrook Terrace, IL
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Shreveport, LA
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Rockville, MD
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Farmington Hills, MI
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
St. Charles, MO
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
St. Charles, MO
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Clementon, NJ
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Clementon, NJ
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Brooklyn, NY
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
New York, NY
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Beachwood, OH
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Beachwood, OH
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Eugene, OR
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Portland, OR
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Memphis, TN
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Austin, TX
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Irving, TX
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Irving, TX
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Lake Jackson, TX
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Lake Jackson, TX
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Bellevue, WA
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated:  4/14/2015
GSK Investigational Site
mi
from
Edmonton,
Study Of GW679769 In Major Depressive Disorder
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.
Status: Enrolling
Updated: 4/14/2015
GSK Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Peoria, AZ
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Peoria, AZ
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Garden Grove, CA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Irvine, CA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
National City, CA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
National City, CA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Miami, FL
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Winter Park, FL
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Springfield, IL
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Terre Haute, IN
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Terre Haute, IN
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Florence, KY
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Florence, KY
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Brockton, MA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Brockton, MA
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
New York, NY
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Chapel Hill, NC
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Raleigh, NC
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Lyndhurst, OH
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Lyndhurst, OH
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Eugene, OR
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated:  4/15/2015
GSK Investigational Site
mi
from
Philadelphia, PA
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Status: Enrolling
Updated: 4/15/2015
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials